Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 52023XC00901

    Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)

    C/2023/7331

    OJ C, C/2023/901, 22.11.2023, ELI: http://data.europa.eu/eli/C/2023/901/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    ELI: http://data.europa.eu/eli/C/2023/901/oj

    European flag

    Official Journal
    of the European Union

    EN

    Series C


    C/2023/901

    22.11.2023

    Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

    (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006  (1) )

    (Text with EEA relevance)

    (C/2023/901)

    Decision granting an authorisation

    Reference of the decision (2)

    Date of decision

    Substance name

    Holder of the authorisation

    Authorisation number

    Authorised use

    Date of expiry of review period

    Reasons for the decision

    C(2023) 7331

    15 November 2023

    4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (4-tert-OPnEO)

    EC No: -, CAS No:-

    RSI ChemRep Europe Ltd, only representative of OraSure Technologies Inc., 27-30 Merchants Quay, Merchants House, Dublin 8, Ireland

    REACH/23/29/0

    As a surfactant in in-vitro diagnostic device developer solution for the diagnosis of Human Immunodeficiency Virus and Hepatitis C Virus

    4 January 2033

    In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies.


    (1)   OJ L 396, 30.12.2006, p. 1.

    (2)  The decision is available on the European Commission website at: Authorisation (europa.eu).


    ELI: http://data.europa.eu/eli/C/2023/901/oj

    ISSN 1977-091X (electronic edition)


    Top